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Abstract
Cytarabine (Ara-C) and Daunorubicin (Dnr) forms the backbone of acute myeloid leukemia
(AML) therapy. Drug resistance and toxic side effects pose a major threat to treatment suc-
cess and hence alternate less toxic therapies are warranted. NF-E2 related factor-2 (Nrf2),
a master regulator of antioxidant response is implicated in chemoresistance in solid tumors.
However, little is known about the role of Nrf2 in AML chemoresistance and the effect of
pharmacological inhibitor brusatol in modulating this resistance. Primary AML samples with
high ex-vivo IC50 to Ara-C, ATO, Dnr had significantly high NRF2 RNA expression. Gene-
specific knockdown of NRF2 improved sensitivity to these drugs in resistant AML cell lines
by decreasing the expression of downstream antioxidant targets of Nrf2 by compromising
the cell’s ability to scavenge the ROS. Treatment with brusatol, a pharmacological inhibitor
of Nrf2, improved sensitivity to Ara-C, ATO, and Dnr and reduced colony formation capacity.
AML cell lines stably overexpressing NRF2 showed increased resistance to ATO, Dnr and
Ara-C and increased expression of downstream targets. This study demonstrates that Nrf2
could be an ideal druggable target in AML, more so to the drugs that function through ROS,
suggesting the possibility of using Nrf2 inhibitors in combination with chemotherapeutic
agents to modulate drug resistance in AML.
Introduction
Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous malignancy
characterized by increased proliferation and defective maturation of the cells of the myeloid
lineage. The frontline treatment for AML (except for AML-M3) involves the combination of
Cytarabine (Ara-C) and Daunorubicin (Dnr). Although ~70–85% of the patients achieve ini-
tial induction remission with this treatment, the 5-year overall survival is only 30–40%, with
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drug resistance being the major cause of the treatment failure [1]. Also, toxic effects to these
drugs limit the success of this therapy in AML patients with pre-existing comorbidities [2].
Moreover, treatment-related mortality is reported in >30% of older AML patients with poor
performance factor receiving standard induction chemotherapy [3] thereby warranting alter-
native less toxic therapies in this group of patients.
Some of the major factors contributing to drug resistance in AML include the persistence
of leukemic stem cells [4], altered expression of drug influx and efflux transporters [5], altered
cell cycle checkpoints [6] and increased antioxidant defense systems[7]. Novel therapeutic
strategies against these targets such as inhibitors of cell cycle proteins [8], pro-apoptotic pro-
teins [9] and drug transporters [10] have been studied to overcome drug resistance. Targeting
the antioxidant defense pathways are also shown to be an effective strategy for eliminating can-
cer cells [11]. Constitutive overexpression of NF-E2 related factor 2 (NFE2L2 or NRF2), the
master regulator of antioxidant pathway genes involved in scavenging and detoxification of
reactive oxygen species (ROS) results in chemoresistance as reported in several solid tumors
([12] [13] [14]). Overexpression of Nrf2 results either from the mutations [15] or epigenetic
modifications [16] in its binding partner KEAP1, transcriptional activation of NRF2 by onco-
genic RAS or c-MYC [17] or due to phosphorylation at the serine, threonine or tyrosine resi-
dues which prevents their ubiquitination [18].
There are limited studies suggesting the role of Nrf2 in mediating chemoresistance in
hematological malignancies. AML cells have been shown to express high nuclear levels of
Nrf2, and its knockdown improved the chemosensitivity to Ara-C and Dnr [19]. Studies in
NCI-60 tumor cell lines panel suggested that Nrf2 mediated oxidative stress response pathways
are enriched in arsenic trioxide (ATO) resistant tumor cell lines [20]. The reduced activity of
ATO on non-M3 AML cells could hence be attributed to the increased expression of Nrf2.
Pharmacological inhibition of Nrf2 has been shown to improve the sensitivity to chemo-
therapeutic agents in non-small cell lung carcinoma, A549 lung cancer, hepatoma and pancre-
atic cancer cell lines [21,22]. Compounds including luteolin, trigonelline and triptolide
showed improved activity against Nrf2 in-vitro and in-vivo [23,24]. Recent report from Peng
et al., suggest that ethionamide suppression of ARE activity sensitised the monocytes to arsenic
therapy [25]. Brusatol, a quassinoid extracted from Brucea javanica was recently identified to
have potent inhibitory activity against Nrf2 protein levels ([26]) by enhancing its ubiquitina-
tion in a KEAP1 (Kelch-like ECH associated protein) independent mechanism. Even though
the effect of Brusatol in inhibiting Nrf2 and improving chemosensitivity was well demon-
strated in solid tumors, its role in hematological malignancies has not been evaluated.
The aim of the present study was to investigate the role of Nrf2 in resistance to Ara-C, Dnr,
and ATO in AML and to demonstrate the effect of pharmacological inhibition of Nrf2 using
Brusatol in modulating the chemoresistance.
Materials and methods
Drugs, chemicals, and antibodies
Cytosine β-D-arabinofuranoside hydrochloride (Ara-C HCl), Daunorubicin hydrochloride
(Dnr HCl) and Methyl thiazolyldiphenyl-tetrazolium bromide (MTT) were obtained from
Sigma-Aldrich (St Louis, MO, USA). Arsenic trioxide (ATO; Arsenox) was purchased from
Intas Pharmaceuticals (Ahmedabad, India). Brusatol (NSC 172924-T/1) was provided by
Developmental Therapeutics Program, National Cancer Institute (NCI-DTP, Bethesda, USA).
All cell culture reagents were obtained from Thermo Scientific (Waltham, MA, USA). Rabbit
polyclonal anti Nrf2 (H300, 1:200) was purchased from Santa Cruz Technologies (CA, USA).
Rabbit monoclonal anti-Nrf2 (D1Z9C, 1:6400) for use in flowcytometry experiments, was
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purchased from Cell Signalling Technologies (Danvers, MA, USA), β Actin (AC-74, 1:5000)
from Sigma-Aldrich (St. Louis, MO), rabbit polyclonal anti-KEAP1 from Cuz Bio
(CSB-PA012147LA01HU) and horseradish peroxidase-conjugated goat anti-Rabbit (1:4000),
goat anti-mouse IgG (1:20,000) secondary antibodies from Thermo Scientific (Waltham, MA,
USA).
Patient samples
Bone marrow samples were collected after obtaining written informed consent from patients
with de-novo AML (excluding AML-M3). This proposal was approved by the Institutional
Review Board (IRB Min No. 8312). Bone marrow mononuclear cells were isolated by Ficoll
density gradient centrifugation.
Cell lines and culture conditions
Human AML cell lines THP1 (National Centre for Cell Science, Pune, India), Molm13 (gift
from Dr. Ellen Weisberg, Dana Farber Cancer Institute, Boston, MA, USA), U937 (gift from
Dr. Stefan Glaser, Cancer and Hematology Division, Walter and Eliza Hall Institute of Medical
Research, Australia) and HL60 (ATCC, CCL-240) were used in this study. Cells were cultured
in RPMI media supplemented with Foetal bovine serum (10%) and antibiotics (100U/ml Peni-
cillin and 100g/ml Streptomycin) in humidified atmosphere with 5% CO2 at 37˚C. THP1 com-
plete growth medium was prepared by supplementing 10% RPMI with β-mercaptoethanol
(0.05 mM).
RNA extraction and real-time quantitative PCR (RQ-PCR)
Total RNA was isolated using Tri-reagent (Sigma St. Louis, MO, USA) and the cDNA was pre-
pared from 1μg of RNA using High Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems, Foster City, CA, USA). Taqman1 Gene Expression Assays (Applied Biosystems,
Foster City, CA) were used to analyze RNA expression of NRF2 (Hs00975960_m1), Heme oxy-
genase (HMOX-1) (Hs01110250_m1), Glutathione cysteine ligase catalytic subunit (GCLC)
(Hs00155249_m1), Glutathione cysteine ligase modifier subunit (GCLM) (Hs00157694_m1),
NADPH Quinone oxidoreductase (NQO1) (Hs02512143_s1) and Glyceraldehyde 3-phosphate
dehydrogenase (Hu GAPDH) (4352934_1101034) with TaqMan1 Universal PCR Master Mix
(Applied Biosystems, Foster City, CA) in an 7500 Fast Real-Time PCR System (Life Technolo-
gies, Carlsbad, CA, USA). Relative gene expression (ΔCt) was calculated by normalizing indi-
vidual gene expression to that of GAPDH. Fold-change expression values were provided as
log-base 2 between control and the test groups. KEAP1RNA expression was analyzed in AML
cell lines using SYBR Green chemistry (SYBR1 Premix Ex Taq™ II (Tli RNaseH Plus), TaKaRa
Bio, Shiga, Japan) and (ΔCt) was calculated by normalizing individual gene expression to that
of β-Actin. Primer sequences for KEAP1 and β-Actin are listed in S1 Table.
In-vitro cytotoxicity assay
Cells were seeded at a density of 105 cells per well of a 96 well flat bottom plate and treated
with increasing concentrations of Ara-C (0.1–80μM), Dnr (0.0025–1μM) or ATO (0.1–6μM).
The plates were incubated for 48hrs in 5% CO2 at 37˚C. Ten μl of MTT reagent was added to
the wells, and the cell viability was measured at standard wavelength 570nm and reference
wavelength 630nm using EL800 reader with KC junior software (Biotek Winooski, VT, USA).
All the experiments were performed in triplicates. The combinatorial index (CI) was calculated
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using Compusyn software (ComboSyn, Inc., Paramus, NJ). CI = 1 indicates additive effect,
CI<1 indicates synergism and CI > 1 indicates antagonism in drug combinations.
Determination of Nrf2 expression and apoptosis by flow cytometry
Flow cytometric estimation of Nrf2 in cells was performed based on manufacturer’s instruc-
tion (Cell Signaling). The cells were stained with rabbit primary monoclonal Nrf2 antibody
and then incubated with anti- rabbit Alexa Fluor antibody (Molecular Probes, Eugene, OR).
Apoptosis was determined by staining the cells with allophycocyanin (APC) conjugated
Annexin V and 7-Amino-Actinomycin (7-AAD) (BD Pharmingen, San Diego, CA) based on
manufacturer’s instruction. The redox status of cells was determined by incubating the cells
with 2’-7’-Dichlorodihydrofluorescein diacetate DCFDA (10μM) (Sigma-Aldrich, St Louis,
MO, USA) for 15min followed by measuring the mean fluorescent intensity (MFI). Flow
cytometry analysis was performed using Accuri C6 cytometer (BD Biosciences, Franklin
Lakes, NJ) with BD Accuri C6 Software (Version 1.0.264.21) and further analysed by flowJO.
Nrf2 protein expression by western blot and subcellular localization by
Immunofluorescence
Cells were washed with ice-cold PBS, and the whole cell lysates were prepared in Radioimmu-
noprecipitation assay (RIPA) buffer supplemented with protease inhibitor mixture (1X)
(Roche Applied Science, IN, USA) and 2mM Phenyl methyl sulfonyl fluoride (Sigma-Aldrich)
(Sigma–Aldrich, Bangalore, India). Protein concentration was estimated using Bradford
method. Total proteins (50μg/lane) were resolved in 10% SDS-Polyacrylamide gel and trans-
ferred to polyvinylidene difluoride (PVDF) membranes. Membranes were blocked with
10% non-fat dry milk powder in TBS containing 0.1% Tween20 and then incubated with
Anti-Nrf2 antibody. β –Actin was used as loading control. The bands were visualized using a
chemiluminescence ECL system (Super Signal West Femto, Thermo Scientific). The intensity
of protein bands was quantified by FluorChem E system using Digital Darkroom software.
Subcellular localization of Nrf2 was determined by immunofluorescence as previously
described [27].
Preparation of nuclear lysate and determination of antioxidant response
element (ARE) binding activity of Nrf2
Nuclear lysates were prepared from cell lines using nuclear extract kit (Active Motif Inc., Carls-
bad, CA, USA). Protein concentration was estimated using Bradford method. Nrf2 binding to
ARE was determined using TransAM Kit based on manufacturer’s instructions (Active Motif
Inc., Carlsbad, CA, USA). Six micro gram of protein were added per well of 96 well plate to
which the oligonucleotide has been immobilized. The spectrophotometric read out was taken
at 450nm and represented as binding activity of Nrf2.
Genomic DNA extraction and sequencing to identify mutations in KEAP1
gene
Genomic DNA was extracted from AML cell lines using phenol-chloroform method. Muta-
tions in KEAP1 (exon 2 to exon 6) was screened by PCR followed by direct sequencing in an
Applied Biosystems Genetic Analyzer 3130 (Foster City, CA, USA). The primer sequences
used for PCR and sequencing are enlisted in S1 Table.
Nrf2 inhibition overcomes chemotherapy resistance in AML
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Knockdown and overexpression of Nrf2
For generating doxycycline-inducible Nrf2 shRNA plasmid, validated shRNA for human Nrf2
(Sigma-Aldrich, St Louis, MO, USA; Cat. No: TRCN0000007555) was cloned into Plko.1 Tet-
ON plasmid (Addgene clone ID 21915). This shRNA showed significantly better knock down
of Nrf2 as reported previously in recent studies [28,29]. For generating Nrf2 overexpression
plasmids, a lentiviral vector containing full-length Nrf2 cDNA, PLX304-Nrf2 (clone ID
HsCD00445044), was purchased from DNASU plasmid repository (Biodesign Institute, Ari-
zona State University, Arizona, USA).
Viral particles were generated by co-transfecting 293T cells with 2μg of PLKO.1-TET-ON-
shNRF2 and 0.5μg each of helper plasmids -psPAX2 (Addgene plasmid no.12260), pMD2.G
(Addgene plasmid no. 12259) using 3μl transfection reagent (Fugene 6, Promega, Madison,
WI). The supernatant containing lentiviruses were collected at 24, 48, 72hrs, pooled, filtered
and frozen at -80˚C until use. Target cell lines (HL60, Molm13, U937, and THP1) were trans-
duced with lentiviruses in the presence of 0.8μg/ml polybrene followed by spinfection to
increase the transduction efficiency.
Nrf2 ShRNA transduced AML cells (THP1 and U937) were selected by puromycin
(1.5μg/ml and 2μg/ml respectively), and the conditional knockdown of Nrf2 was achieved by
the addition of doxycycline (1μg/ml). For cell lines transduced with full-length Nrf2 cDNA,
cells were challenged with blasticidin S (2μg/ml for HL60 and 5μg/ml for Molm13) for seven
days and blasticidin resistant cells were collected.
Effect of brusatol treatment in combination with chemotherapeutic drugs
on primary AML and normal BMMNCs
BMMNCs isolated from AML primary samples (n = 10) as well as normal healthy volunteers
were incubated with 10nM of Brusatol followed by Ara-C, Dnr and ATO treatment for 48h.
Cell viability was assessed by MTT assay and IC-50 was calculated.
Clonogenicity by methylcellulose assay
THP1 cells (10X106) incubated with and without Brusatol were seeded in methylcellulose
(5X103) (Stem cell Technologies, Vancouver, Canada), colonies were visualized and enumer-
ated after ten days.
Statistical analysis
Unpaired t-test, non-parametric t-test and ANOVA with Kruskal- Wallis correction were used
where appropriate. All statistical analysis was done using GraphPad Prism software and p-
value < 0.05 was considered as statistically significant.
Results
High Nrf2 expression is associated with chemoresistance to Ara-C, Dnr,
and ATO in AML cell lines and primary AML cells
To understand the role of Nrf2 in chemoresistance, we compared the RNA expression of
NRF2 in primary AML cells to their ex vivo sensitivity to Ara-C, Dnr, and ATO. Primary AML
samples were grouped according to their median IC50 values (Ara-C 6μM, Dnr 0.4μM and
ATO 2.42μM). Primary AML samples with Ara-C, Dnr or ATO IC50 above the median had
significantly higher NRF2 RNA expression (p = 0.07, 0.004 and 0.01 respectively) compared to
those below median (Fig 1A). Further, we compared the in-vitro sensitivity of AML cell lines
to Ara-C, Dnr and ATO with NRF2 RNA expression levels. Among the cell lines studied,
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THP1 and U937 with high IC50 values to all these three drugs also expressed high mRNA lev-
els of NRF2 compared to the cell lines Molm13 and HL60 with low IC50 values (Fig 1B). Flow
cytometry analysis also revealed elevated intracellular protein levels of Nrf2 in THP1 and
U937 compared to the sensitive cell lines HL60 and MOLM13 (Fig 1C & S1 Fig). Total and
nuclear Nrf2 protein expression was higher in the resistant cell lines THP1 and U937 com-
pared to Molm13 and HL60 as shown by immunoblot and immunofluorescence (Fig 1D and
1E). When the activation of Nrf2 mediated antioxidant response in these cells was investigated,
the transcript levels of Nrf2 downstream targets GCLC, GCLM, NQO1,HMOX-1 genes were
high in resistant cell lines compared to the sensitive cell lines (Fig 1F).
Nrf2 overexpression in AML cell lines is independent of KEAP1
mutations and expression
As KEAP1 mutations are shown to be causing Nrf2 up-regulation, we screened for the pres-
ence of mutations in KEAP1 (exon 2-exon 6) in AML cell lines. We did not identify any
Fig 1. Primary AML cells and cell lines resistant to cytarabine, daunorubicin and arsenic trioxide
show increased Nrf2 expression. (A) AML samples categorised based on median IC50 values to Ara-C
(6μM), Dnr (0.4μM) and ATO (2.42μM) were analysed for the expression of NRF2 by quantitative real time
PCR. Y axis denotes relative expression (2^-dCT) of NRF2 normalised to GAPDH. (B) NRF2 levels in AML
cell lines resistant (THP1, U937) or sensitive (HL-60, MOLM-13) to Ara-C, Dnr and ATO were analysed and
represented as fold change (2^-ddCT) normalised to Molm13 (with low NRF2 RNA)} (n = 5). *Statistical
significance were calculated based on Kruskal–Wallis test and p<0.05 is indicated. (C) Flow cytometric
analysis of total Nrf2 expression in AML cell lines (n = 4). (D) Immunofluorescence analysis of nuclear Nrf2
expression in AML cell lines {40,6-diamidino-2-phenylindole (blue) and Nrf2 antibody (red) stained images
overlay} (n = 2). (E) Immunoblotting of total Nrf2 in AML cell lines (β-actin was used as loading control) (n = 3).
(F) Nrf2 downstream target expression {(HO-1, NQO1, GCLC and GCLM) normalized to GAPDH and
expressed relative to that of MOLM-13 cell line (n = 4)}.*Statistical significance were calculated based on
Kruskal–Wallis test and p<0.05 is indicated.
https://doi.org/10.1371/journal.pone.0177227.g001
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mutation in the exonic regions of KEAP1 in all the cell lines screened (data not shown) sug-
gesting that Nrf2 overexpression in AML is not due to KEAP1 mutations. We then compared
the mRNA and protein expression of KEAP1 in these cell lines. We observed that neither
KEAP1 mRNA nor protein expression was significantly different between sensitive and resis-
tant cell lines. (S2A and S2B Fig).
Knockdown of Nrf2 sensitizes AML cell lines to Dnr and ATO by reducing
the reactive oxygen scavenging capacity and down-regulation of target
antioxidant genes
To further investigate the role of Nrf2 in chemoresistance, we determined the effect of Nrf2
knockdown on sensitivity to Ara-C, Dnr, and ATO in the cell lines THP1, U937 with a high
endogenous expression of Nrf2. As the constitutive knockdown of Nrf2 reduced the cell prolif-
eration over time (as determined by trypan blue dye staining), we developed a conditional
Nrf2 knockdown system. We did not observe any cell death (by trypan blue dye staining) or
difference in the stages of cell cycle (S3A Fig upper panel) by the inducible knockdown system
during the period of study. However, we observed nearly 30% apoptosis upon continuous
long-term doxycycline exposure (S3A Fig lower panel). Using this system, we achieved 60–
80% decrease in the Nrf2 RNA levels (Fig 2A) as well as total and subcellular protein expres-
sion (Fig 2B–2D) compared to the doxycycline negative control cells. As expected, we observed
Fig 2. Conditional knockdown of NRF2 reduces the total cellular and subcellular expression of Nrf2
as well as downstream target gene expression in AML cell lines. THP1 and U937 cells (with relatively
high expression of Nrf2) were transduced with doxycycline-inducible Nrf2 shRNA system treated (+) or not
treated (-) with Doxycycline. (A) RNA was extracted, and the expression of NRF2 (normalized to GAPDH
mRNA levels) was evaluated. Y axis represents NRF2 expression (2^-ddCT) normalized to Dox- control cells
(n = 4). *Statistical significance were calculated based on unpaired t test and p<0.05 is indicated. (B) Total
protein levels of Nrf2 in THP1 and U973 (knockdown and control) cell lines was analysed by flow cytometry
(n = 3). (C) THP1 cells were lysed, whole cell proteins were extracted, and 50μg of protein was resolved by
SDS-PAGE; β—actin was used as loading control (n = 4) (D) subcellular localisation of Nrf2 was analysed by
immunofluorescence {40, 6-diamidino-2-phenylindole (blue) and Nrf2 antibody (red) stained images overlay}
(n = 2) and (E) transcript levels of NRF2 downstream target genes (HO-1, NQO1, GCLC and GCLM) were
analysed by real-time PCR. RNA expression of all target genes was normalized to GAPDH (n = 4). *Statistical
significance were calculated based on unpaired t test and p<0.05 is indicated.
https://doi.org/10.1371/journal.pone.0177227.g002
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a concomitant decrease in the expression of Nrf2 downstream target genes GCLC, GCLM,
HMOX-1, and NQO1 (1.1, 1.6, 1.5 and 1.8 folds respectively) compared to Dox-control cells
(Fig 2E). Doxycycline did not have any independent effect in reducing the Nrf2 levels as
assessed by flow cytometry (S4 Fig). Knockdown of Nrf2 improved the in-vitro sensitivity of
AML cell lines to Dnr (Fig 3A) and ATO (Fig 3B) as shown by their IC50 values (Fig 3C).
However, we did not observe significant improvement in sensitivity to Ara-C in both THP1
and U937 cells compared to control cells (S5A Fig). Chemotherapeutic agents bring about cell
kill by escalating the reactive oxygen species (ROS). When basal levels of Nrf2 is high, levels of
ROS in cells does not cross the toxic threshold levels. We assessed whether Nrf2 knockdown
compromises the cell’s ability to scavenge the ROS. Upon silencing of Nrf2 followed by treat-
ment with chemotherapeutic agents (ATO and Dnr), we observed that accumulation of ROS
was much higher in the knockdown cells compared to the control cells (Fig 3D) although only
subtle increase in ROS levels was noted after treatment with Ara-C (S5B Fig).
Pharmacological inhibition of Nrf2 brings down Nrf2 expression and
induces early apoptosis in AML cells
To determine the effect of pharmacological inhibition of Nrf2 in modulating chemoresistance,
we tested the combinatorial effect of Nrf2 inhibitors with Ara-C, Dnr, and ATO. Among the
compounds screened for inhibitory activity against Nrf2 (S6 Fig), brusatol was found to be the
most efficient inhibitor of Nrf2 (Fig 4A). The effect of this compound in reducing the elevated
Nrf2 levels in a dose and time-dependent manner was assessed in THP1 cell line. We observed
a considerable reduction in total and subcellular Nrf2 levels with brusatol treatment (Fig 4A).
As Nrf2 activation of antioxidant enzymes is achieved through their binding with the
Fig 3. ShRNA knockdown of NRF2 in AML cell line THP1 improved their sensitivity to Dnr, ATO and
reduced IC50 by increasing ROS levels. THP1 and U937 cells (Dox+ and Dox-) were incubated with
increasing concentration of Dnr (A) and ATO (B) for 48hrs and the in-vitro cytotoxicity was measured by MTT
assay (n = 9). (C) IC-50 of Dox+ cells to Dnr and ATO was compared with Dox- cells. (D) THP1 cells were
treated with Dnr (1μM) for 3hrs or ATO (6μM) for 6hrs, washed with PBS and incubated for 15 minutes with
10μM of H2DCFDA. ROS production was analyzed by flow cytometry (n = 3). Mean fluorescence (MFI) was
calculated and compared with Dox- cells. *Statistical significance were calculated based on unpaired t test
and p<0.05 is indicated.
https://doi.org/10.1371/journal.pone.0177227.g003
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antioxidant response elements (ARE), we evaluated the ARE binding activity of Nrf2 after
treatment with Brusatol. We observed that in THP1 cell line, ARE binding activity decreased
moderately upon treatment with Brusatol similar to that of Nrf2 knock down THP1 cells (S7A
Fig). While treatment with chemotherapeutic agents (Ara-C, Dnr and ATO) increased the
ARE binding activity of Nrf2 (S7B–S7D Fig) and thereby the expression of Nrf2 downstream
target (S7E Fig), treatment with brusatol followed by administration of chemotherapeutic
agents reduced the ARE binding of Nrf2. Among them, the binding activity was considerably
reduced with Dnr but to a lesser extent with Ara-C and ATO treatment. As expected, Nrf2
inhibition by brusatol also reduced the transcript levels of Nrf2 downstream targets GCLC,
GCLM, HMOX-1, and NQO1 (by 1.44, 1.93, 1.16 and 2.33 folds respectively) compared to the
control (Fig 4B). To determine the effect of this compound on apoptosis, the cells were incu-
bated with 1000nM and 100nM brusatol for 16hrs followed by Annexin V 7AAD measure-
ment. We observed that brusatol at low concentration (100nM) did not bring about apoptosis.
Moreover, at higher concentration Brusatol (1000nM) had minimal effects in bringing about
early apoptosis (23.7%) and no effects on late apoptosis (Fig 4C) (S8 Fig). When tested for the
effect of pharmacological inhibition of Nrf2 on chemosensitivity of AML cell lines, primary
AML cells as well as normal BMMNCs, we observed that co-administration of brusatol in
resistant AML cell lines expressing high levels of NRF2 (THP1 and U937) followed by ATO,
Ara-C and Dnr improved their sensitivity to these drugs (Fig 5A–5D and S9A–S9C Fig).
Fig 4. Brusatol treatment brings down Nrf2 expression and reduces colony forming capacity of THP1
cells. THP1 cells were treated with 1μM of brusatol reconstituted in DMSO (final concentration of 0.01%) for
6hrs. The expression of Nrf2 after treatment with brusatol was assessed by (A) flow cytometry (n = 2) (i),
western blot with β—actin as the loading control (n = 3) (ii) and subcellular expression (iii). (B) THP1 cells
were treated with 100nM of Brusatol for 6h and downstream targets of Nrf2 GCLC, GCLM, HO-1, and NQO1
was evaluated by quantitative real time PCR (n = 4). RNA expression of all target genes was normalized to
GAPDH. *Statistical significance were calculated based on unpaired t test and p<0.05 is indicated. (C)
Apoptosis upon incubation with two different concentrations 100nM and 1000nM of Brusatol was assessed by
Annexin V-7AAD.
https://doi.org/10.1371/journal.pone.0177227.g004
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Majority of the primary AML samples, showed improved sensitivity to treatment with chemo-
therapeutic agent when brusatol was co-administered (S2 Table). However, brusatol had no
detrimental effect in cell viability in normal donor cells as assessed by in-vitro cytotoxicity. To
further test the effect of brusatol in bringing down the colony forming capacity of AML cells,
brusatol treated and untreated cells were plated on methylcellulose medium. We observed that
brusatol as a single agent reduced the colony numbers compared to control (480±10 vs.
600±11). Even though ATO, Ara-C or Dnr treatment alone reduced the colony number (to
560+40, 481+20 and 7±2 respectively), in combination with brusatol colonies were further
reduced (246+6, 311+5 and 1+1 respectively) (Fig 5E).
Overexpression of NRF2 induces resistance of AML cells to Ara-C, Dnr,
and ATO and attenuates their sensitivity to Nrf2 inhibitors
To further establish the specific role of Nrf2 in chemoresistance to Ara-C, Dnr, and ATO,
NRF2 was overexpressed in AML cell lines using lentiviral expression system. Overexpression
was confirmed by immunoblot and RQ-PCR. We observed an increase in the levels of Nrf2
both at the transcript and protein levels compared to the control (Fig 6A). Expression of Nrf2
downstream targets, GCLC, GCLM, NQO1 except HMOX-1 was found to be elevated in over-
expressed cells (Fig 6B). Constitutive Nrf2 overexpression also increased resistance to ATO
and Dnr as indicated by increased cell viability (Fig 6C).
Discussion
Nrf2 is a redox-dependent transcription factor regulating several antioxidants and phase II
detoxifying genes thereby protecting the cells from oxidative or electrophilic insults. Previous
reports in AML, and other solid tumors have shown that Nrf2 is associated with resistance to
chemotherapeutic agents [30]. Although the previous studies have compared the Nrf2 expres-
sion in AML cells with normal CD34+ cells, they have not compared Nrf2 levels within the
AML population. In primary AML samples at diagnosis, we observed that samples with IC50
Fig 5. Pharmacological inhibition of Nrf2 with brusatol brings down the IC50 of Ara-C, Dnr & ATO in
resistant AML cell lines. THP1 cells were incubated with Nrf2 inhibitor Brusatol 100nM for 6hrs, followed by
increasing concentration of (A) Ara-C (0.1–80μM), (B) Dnr (0.0025–1μM) and (C) ATO (0.1–6μM) for 48hrs.
In-vitro cytotoxicity was measured by MTT assay (n = 9). (D) IC50 of THP1 to Dnr and ATO was compared
with untreated control cells. (E) THP1 cells were incubate with 100nM of Brusatol followed by treatment with
5μM of Ara-C, 0.25μM of Dnr or 6μM of ATO for 24hrs. Control and treated (5*103) cells were seeded in
methyl cellulose medium (n = 2) and enumerated on day 14. Light microscopic images of colonies were taken
on day 14 (10X magnification) (i). Control or treated (5*103) cells seeded in methyl cellulose medium were
stained with methylene blue (ii) and colonies were enumerated (n = 2)(iii). Brusatol alone minimally reduces
the colony forming capacity of THP1 cells and considerably reduces in combination with Ara-C, Dnr and ATO.
https://doi.org/10.1371/journal.pone.0177227.g005
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values to Ara-C, Dnr, and ATO above the median had high NRF2mRNA expression com-
pared to those below the median suggesting that Nrf2 is aberrantly expressed in resistant AML
samples.
In this study, we explored the mechanisms behind Nrf2 upregulation in AML samples. As
mutations in KEAP1 gene have been shown to result in upregulation of Nrf2 as shown in sev-
eral solid tumors [31], we screened for KEAP1 mutations in AML cell lines. We did not detect
any mutations in the KEAP1 gene which was in concordance with the findings from Rush-
worth et al., [32]. The mRNA and protein expression of KEAP1 were also not significantly dif-
ferent between sensitive and resistant cell lines. Hence, we looked at KEAP1 independent
mechanisms of Nrf2 activation. As PI3/AKT/GSK axis being a prominent pathway inducing
Nrf2 activation [33] and as Akt inhibitor, MK2206 has been shown effective in reducing Nrf2
accumulation in A549 lung carcinoma cells [34], we tested the effect of Nrf2 inhibition with
MK2206 in AML cells. However, in AML cells even at pharmacologically relevant concentra-
tion of MK2206, we did not find any considerable reduction in Nrf2 levels, suggesting that
unlike in solid tumors, Nrf2 regulation in AML is not mediated via PI3/Akt pathway.
To further understand the mechanistic role of Nrf2 in chemoresistance, gene-specific
knockdown of Nrf2 was carried out. Unlike previous studies which have attempted transient
knockdown, we used much efficient constitutive system of knockdown of Nrf2 [35,36]. The
efficiency of knockdown in HeLa and MCF7 cells using this method resulted in complete
absence of Nrf2 protein expression. In contrast to solid tumors, Nrf2 shRNA transduction in
AML cells brought about increased cell death which was efficiently rescued by inducible
knockdown suggesting that Nrf2 provides survival advantage to AML cells. These results are
similar to that of Peng et al [25], although these authors used a stable constitutive knockdown
of NRF2 unlike that of ours which is an inducible system.
Previous studies have reported that knockdown of Nrf2 sensitized AML cells to Ara-C and
Dnr in combination. However, we evaluated the role of Nrf2 in sensitizing cells individually to
the drugs Ara-C, Dnr, and ATO. We observed that silencing Nrf2 sensitized AML cells to Dnr
and ATO but not so much to Ara-C. Also, the escalation of ROS levels upon Nrf2 knockdown
was less in Ara-C treated cells. These findings suggest that Nrf2 plays relatively minimal role in
Ara-C resistance than to Dnr and ATO.
Pharmacological inhibition of Nrf2 using flavonoid compounds have been tried in several
tumors [37], but limited reports are available with respect to AML [23,25]. Here we have used
Fig 6. NRF2 overexpression in AML cell lines increases IC50 of ATO & Dnr by up-regulating
downstream target expression. Two AML cell lines (HL-60 and MOLM-13) with relatively low expression of
NRF2 were made to stably over express NRF2. (A) Overexpression was further confirmed by quantitative
real-time PCR (i) and western blot (ii) for Nrf2 (B) Nrf2 downstream target genes (GCLC, GCLM, NQO1, and
HMOX-1) were analyzed by real time quantitative PCR. (C) In-vitro cytotoxicity of overexpressed cells to Dnr
and ATO was compared with control cells. Overexpression increases resistance to Dnr and ATO.
https://doi.org/10.1371/journal.pone.0177227.g006
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brusatol which has been shown in solid tumors to significantly improve sensitivity to doxoru-
bicin, oxaliplatin, and bleomycin by reducing the ARE activity [22]. Among the various phar-
macological Nrf2 inhibitors screened, including MK2206, Luteolin, and U0126, brusatol
showed maximum inhibition of Nrf2 in AML cells. Luteolin having shown to reduce ARE
activity in NSCLC was tested for its effect in AML cell lines. Luteolin did not reduce Nrf2
expression considerably but independently reduced cell viability of FLT3-ITD mutated
(Molm13, Molm-14, and MV4-11), and c-kit mutated (Kasumi-1) AML cell lines by ~50%.
Even though MK2206 treatment did not significantly reduce Nrf2 expression, this resulted in
increased cytotoxicity in FLT3-ITD mutated cell lines as expected.
Apart from their role in improving chemosensitivity, brusatol also enhanced the potential
of cisplatin to reduce the colony formation in A549 lung cancer cells [26]. Similar to this obser-
vation, brusatol treatment in AML cells either alone or in combination with chemotherapeutic
agents considerably reduced colony forming capacity of these cells. However, the mechanism
of action of brusatol in improving chemoresistance in AML needs to be further explored.
As Nrf2 is proven to play a pivotal in chemoresistance, we have assessed the effect of overex-
pression of Nrf2 on the chemoresistance to Ara-C, ATO, and Dnr in AML cell lines. We
observed in Nrf2 overexpressed cell lines an increased functional effect is achieved only after
stabilization of Nrf2 using the compound, tert butinyl hydroxyl quinone (tBHQ). This suggests
that apart from activation, stabilization of Nrf2 determines its function. Although brusatol was
shown to reduce Nrf2 protein levels, its mechanistic role and toxicity profile remains unclear.
Also, the efficacy of the drug needs to be further demonstrated with in-vivo models. The effi-
cacy of Nrf2 inhibitors like triptolide in reducing LSC like cells was shown to have better thera-
peutic potential in treating relapsed and refractory AML [23]. Even though this study shows a
possible role of the Brusatol in reducing colony formation capacity of AML cells, we did not
address their role in specific to leukemic stem cells (CD34+38-) in AML. Another major limi-
tation of this study is that all the experiments were performed in AML cell lines and primary
AML cells while this study would greatly benefit from evaluation of single and combination
therapy in mouse models of AML.
In conclusion, our study demonstrates that Nrf2 could be an ideal druggable target in AML,
more so to the drugs that function through ROS. This study suggests the possibility of using
Nrf2 inhibitors like brusatol in combination with chemotherapeutic agents to modulate drug
resistance in AML.
Supporting information
S1 Fig. Total protein level Nrf2 in AML cell lines were measured by flow cytometry. Cells
were fixed and permeabilized and incubated with Nrf2 antibody. Cells were then stained with
a fluorochrome-tagged secondary antibody, and fluorescence intensity was measured. Values
represent mean ± SD of four independent experiments. Fluorescence intensity of resistant cell
lines THP1 and U937 was compared with sensitive cell lines HL60, MOLM13, and statistical
significance was determined by Kruskal Wallis test. Statistical significance (p<0.05) is indi-
cated.
(TIF)
S2 Fig. KEAP1 expression in AML cell lines. Keap1 expression at protein level (A) and
mRNA level (B) were not significantly different between resistant and sensitive AML cell lines.
Keap1 RNA expression was normalised to β-Actin and expressed in dCT, where higher the
dCt lower the expression and vice versa.
(TIF)
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S3 Fig. shRNA knockdown of NRF2 in AML cell line THP1 did not affect cell cycle initially
but increased the apoptosis at later time periods. (A)THP1 cells after NRF2 knockdown was
incubated with PI for 15min. G1/S/G2M was analyzed in control and knockdown cells. Sub
G0 phase which relates to apoptosis was measured and compared with Dox-control cells.
(TIF)
S4 Fig. Doxycycline did not have any independent effect in reducing the Nrf2 levels. THP1
and U937 cells (1106) were treated with Doxycycline (1μg/ml) for 24h and Nrf2 expression
was determined by flow cytometry. The Nrf2 expression levels were compared with untreated
cells.
(TIF)
S5 Fig. shRNA knockdown of NRF2 in AML cell line THP1 and U937 did not significantly
improve their sensitivity to Ara-C. shRNA knock down of NRF2 in THP1 cells showed
reduced ROS levels compared to control cells. (A) The in-vitro sensitivity of knockdown cells
to Ara-C was measured by MTT assay in THP1 (upper panel) and U937 (lower panel). (B)
THP1 cells were incubated with 5μM of Ara-C for 6hrs and washed with PBS, incubated for 15
minutes with 10μM of H2DCFDA. ROS production was analyzed by flow cytometry.
(TIF)
S6 Fig. U0126 (MEK inhibitor), MK2206 (Akt inhibitor) and luteolin does not consider-
ably bring down Nrf2 expression. AML cell line THP1 was treated with (A) 10μM of
MK2206 (B) 10μM of U0126 or (C) 40μM of Luteolin for 24hrs and expression of Nrf2 was
measured by flow cytometry.
(TIF)
S7 Fig. Brusatol reduced the ARE binding activity of Nrf2 which was increased upon treat-
ment with chemotherapeutic agents. AML cell line THP1 was treated with and without
100nM of Brusatol for 6h. This was followed by treatment with Ara-C (5μM), Dnr (1μM) and
ATO (6μM) for another 24h. Nuclear lysates were quantified and 6μg of protein was added per
well. Nuclear lysates were also prepared from Nrf2 knock down THP1 cells. ARE binding
activity was determined spectrophotometrically at 450nm. (A) Brusatol effectively reduced the
ARE binding activity of Nrf2; similar effect was observed in Nrf2 knock down THP1 cells.
Treatment of THP1 cells with chemotherapeutic agents Ara-C (B), Dnr (C) and ATO (D)
increased the ARE activity as well as expression of downstream targets (E), while Brusatol co
treatment reduced this activity. Brusatol reduced ARE activity moderately in Dnr and mini-
mally in ATO and Ara-C treated cells.
(TIF)
S8 Fig. Brusatol at high concentration induced early apoptosis in THP1 cells. THP1 cells
were treated with two different concentrations of Brusatol (100nM & 1000nM) and incubated
for 6hrs. After incubation, cells were washed and stained with Annexin V 7AAD and the apo-
ptosis was measured. Values represent mean ± SD of two independent experiments.
(TIF)
S9 Fig. Pharmacological inhibition of Nrf2 using brusatol brings down the IC50 of Ara-C,
Dnr & ATO in U937 cell line. U937 cells were incubated with Nrf2 inhibitor Brusatol 100nM
for 6hrs, followed by increasing concentration of (A) Ara-C, (B) Dnr and (C) ATO for 48hrs.
In-vitro cytotoxicity was measured by MTT assay.
(TIF)
Nrf2 inhibition overcomes chemotherapy resistance in AML
PLOS ONE | https://doi.org/10.1371/journal.pone.0177227 May 15, 2017 13 / 16
S1 Table. List of primers used for Nrf2 and Keap1 sequencing.
(TIF)
S2 Table. Brusatol sensitized AML primary cells to Ara-C, Dnr and ATO. Primary samples
at diagnosis was subjected to pre-treatment with brusatol followed by increasing concentra-
tions of (A) Ara-C (0.1–80μM), (B) Dnr (0.0025–1μM) and (C) ATO (0.1–6μM) for 48h.
Ex -vivo cytotoxicity was measured by MTT assay.
(TIF)
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